blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3212232

EP3212232 - TETRAVALENT TLR9 BISPECIFIC ANTIBODY [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  05.03.2021
Database last updated on 24.07.2024
FormerExamination is in progress
Status updated on  22.06.2020
FormerRequest for examination was made
Status updated on  04.08.2017
FormerThe international publication has been made
Status updated on  31.05.2017
Most recent event   Tooltip05.03.2021Application deemed to be withdrawnpublished on 07.04.2021  [2021/14]
Applicant(s)For all designated states
H. Lee Moffitt Cancer Center And Research Institute, Inc.
12902 Magnolia Drive
Tampa, FL 33612 / US
[2017/36]
Inventor(s)01 / LIST, Alan F.
15706 Cochester Road
Tampa Florida 33647 / US
02 / WEI, Sheng
16330 Burniston Drive
Tampa Florida 33647 / US
 [2017/36]
Representative(s)Moré, Solveig Helga, et al
Kroher Strobel
Rechts- und Patentanwälte PartmbB
Bavariaring 20
80336 München / DE
[N/P]
Former [2017/36]Friedrich, Rainer
Df-mp Dörries Frank-Molnia & Pohlman
Patentanwälte Rechtsanwälte PartG mbB
Fünf Höfe / Theatinerstraße 16
80333 München / DE
Application number, filing date15855682.930.10.2015
[2017/36]
WO2015US58263
Priority number, dateUS201462073796P31.10.2014         Original published format: US 201462073796 P
US201562221452P21.09.2015         Original published format: US 201562221452 P
[2017/36]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2016070014
Date:06.05.2016
Language:EN
[2016/18]
Type: A1 Application with search report 
No.:EP3212232
Date:06.09.2017
Language:EN
The application published by WIPO in one of the EPO official languages on 06.05.2016 takes the place of the publication of the European patent application.
[2017/36]
Search report(s)International search report - published on:US06.05.2016
(Supplementary) European search report - dispatched on:EP21.12.2018
ClassificationIPC:A61K39/395, A61P35/00, C07K14/705, C07K16/28, A61K35/00, A61K39/00, C07K16/30
[2019/04]
CPC:
A61K39/39533 (EP,US); C07K16/30 (US); A61K35/00 (US);
A61K39/395 (EP,US); A61K48/0008 (US); A61P35/00 (EP);
C07K14/70596 (EP,US); C07K16/28 (EP,US); C07K16/2809 (US);
C07K16/2866 (US); C07K16/2896 (US); A61K2039/505 (US);
C07K2317/31 (US); C07K2317/35 (US); C07K2317/56 (US);
C07K2319/02 (US); C07K2319/03 (US); C07K2319/33 (US);
C07K2319/40 (US); C07K2319/74 (US) (-)
Former IPC [2017/36]A61K39/395, A61P35/00, C07K14/705, C07K16/28
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2017/36]
TitleGerman:TETRAVALENTE TLR9-BISPEZIFISCHE ANTIKÖRPER[2017/36]
English:TETRAVALENT TLR9 BISPECIFIC ANTIBODY[2017/36]
French:ANTICORPS BISPÉCIFIQUE TÉTRAVALENT ANTI-TLR9[2017/36]
Entry into regional phase31.05.2017National basic fee paid 
31.05.2017Search fee paid 
31.05.2017Designation fee(s) paid 
31.05.2017Examination fee paid 
Examination procedure31.05.2017Examination requested  [2017/36]
31.05.2017Date on which the examining division has become responsible
16.07.2019Amendment by applicant (claims and/or description)
25.06.2020Despatch of a communication from the examining division (Time limit: M04)
06.11.2020Application deemed to be withdrawn, date of legal effect  [2021/14]
26.11.2020Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time  [2021/14]
Fees paidRenewal fee
30.05.2018Renewal fee patent year 03
29.10.2018Renewal fee patent year 04
28.10.2019Renewal fee patent year 05
14.10.2020Renewal fee patent year 06
Penalty fee
Additional fee for renewal fee
31.10.201703   M06   Fee paid on   30.05.2018
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[Y]WO0171005  (KUFER PETER [DE], et al) [Y] 1-6 * page 5, last paragraph;; figure 2; claims 1-43 *;
 [Y]US2004023870  (DEDERA DOUGLAS [US], et al) [Y] 5 * [0002], [0197];; examples 7, 12; claims 1-25 *;
 [Y]EP2361936  (AFFIMED THERAPEUTICS AG [DE]) [Y] 1-6 * [0002],[0009], [0029];; claims 1-15; table 1 *;
 [Y]WO2012162561  (ZYNGENIA INC [US], et al) [Y] 2 * CD3: [00023, 00127, 00413-00416] TLR3: [00310, 00609] *;
 [A]WO2013104804  (UNIV WUERZBURG J MAXIMILIANS [DE]) [A] 1-15 * claims 1-46 *;
 [Y]US2013243767  (MUDDE GEERT [AT], et al) [Y] 1-15 * [0003, 0013, 0014, 0026, 0036, 0037,0052,0055 0064, 0081 ];; claims 1-32 *;
 [Y]US2014065142  (ROSCHKE VIKTOR [US], et al) [Y] 2 * [0020, 0024, 0026, 0118, 0313] *;
 [Y]WO2014113802  (H LEE MOFFITT CANCER CT & RES [US]) [Y] 1-6 * figure 4; claims 1-12 *;
 [Y]US2014322212  (BROGDON JENNIFER [US], et al) [Y] 7-15* [0006], claims 1, 37 91 *;
 [Y]  - Qifang Zhang ET AL, "TLR9-mediated siRNA delivery for targeting of normal and malignant human hematopoietic cells in vivo", Blood, doi:10.1182/blood-2012-07-, (20130101), pages 1304 - 1315, URL: http://www.bloodjournal.org/content/bloodjournal/121/8/1304.full.pdf?sso-checked=true, (20180604), XP055480700 [Y] 7 * abstract * * page 1305, column 1, 2nd paragraph, 2nd sentence *

DOI:   http://dx.doi.org/10.1182/blood-2012-07-
International search[XY]US2013243767  (MUDDE GEERT [AT], et al) [X] 1, 3, (10-12)/1 * para [0012], [0026], [0036], [0037], [0052], [0055], [0057], [0061]. [0069], [0071]. [0081], [0074]. [0075], [0081 [0114], [0217]; claim 19 * [Y] 2, 4, 5, (10-12)/2, 13, 15- 17;
 [Y]US2014065142  (ROSCHKE VIKTOR [US], et al) [Y] 2, 4, 5, (10-12)/2, 13, (15- 17)/2 * para [0020], [0024], [0026] [0118], [0129], [0152], [0154], [0313], [0610], [0679] *;
 [Y]WO2014113802  (H LEE MOFFITT CANCER CT & RES [US]) [Y] (15-16)/1, 17, 19-23 * p 2, In 11-12; p 6, In 12-13 *;
 [Y]US2014322212  (BROGDON JENNIFER [US], et al) [Y] 19-23* para [0003], [0006], [0097], [0101]. [0173], [0175], [0225], [0231], [0241], [0303]. [0318], [0320] *
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.